Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Integra Lifesciences Holdings (IART) EBITDA Margin (2016 - 2025)

Integra Lifesciences Holdings (IART) has disclosed EBITDA Margin for 17 consecutive years, with 5.3% as the latest value for Q4 2025.

  • Quarterly EBITDA Margin fell 275.0% to 5.3% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 30.34% through Dec 2025, down 3031.0% year-over-year, with the annual reading at 30.17% for FY2025, 3194.0% down from the prior year.
  • EBITDA Margin hit 5.3% in Q4 2025 for Integra Lifesciences Holdings, up from 1.61% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 21.06% in Q1 2021 to a low of 118.11% in Q2 2025.
  • Historically, EBITDA Margin has averaged 0.65% across 5 years, with a median of 6.44% in 2023.
  • Biggest five-year swings in EBITDA Margin: surged 2642bps in 2021 and later plummeted -11321bps in 2025.
  • Year by year, EBITDA Margin stood at 14.36% in 2021, then rose by 19bps to 17.04% in 2022, then crashed by -47bps to 9.08% in 2023, then dropped by -11bps to 8.05% in 2024, then crashed by -34bps to 5.3% in 2025.
  • Business Quant data shows EBITDA Margin for IART at 5.3% in Q4 2025, 1.61% in Q3 2025, and 118.11% in Q2 2025.